Revenue: As of FY2026 Q1, the actual value is USD 0.EPS: As of FY2026 Q1, the actual value is USD -0.28, beating the estimate of USD -0.45.EBIT: As of FY2026 Q1, the actual value is USD -2.341 M.<h4>Financial Results for the Three Months Ended December 31, 2025</h4><ul><li>Total Operating Expenses: Increased by $0.4 million to $2.3 million for the three months ended December 31, 2025, compared to $1.9 million for the same period in the previous year .<ul><li>Research and Development Expenses: Increased by $0.1 million to $1.1 million for the three months ended December 31, 2025, compared to $1.0 million for the same period last year .</li><li>General and Administrative Expenses: Increased by $0.3 million to $1.2 million for the three months ended December 31, 2025, compared to $0.9 million for the same period last year .</li></ul></li><li>Loss from Operations: -$2,341,383 for the three months ended December 31, 2025, compared to -$1,898,689 for the three months ended December 31, 2024 .</li><li>Total Other Income: Decreased by $0.2 million to $0.1 million for the three months ended December 31, 2025, compared to $0.3 million for the same period last year .<ul><li>Reimbursement Grant Income: $102,425 for the three months ended December 31, 2025, compared to $301,195 for the three months ended December 31, 2024 .</li><li>Other Income (Loss): -$8,711 for the three months ended December 31, 2025, compared to -$19,759 for the three months ended December 31, 2024 .</li></ul></li><li>Net Loss: Edesa Biotech, Inc. reported a net loss of -$2.2 million for the quarter ended December 31, 2025, compared to a net loss of -$1.6 million for the quarter ended December 31, 2024 .</li><li>Net Comprehensive Loss: -$2,252,984 for the three months ended December 31, 2025, compared to -$1,598,597 for the three months ended December 31, 2024 .</li></ul><h4>Working Capital</h4><ul><li>Cash and Cash Equivalents: $12.1 million as of December 31, 2025 .</li><li>Working Capital: $12.0 million as of December 31, 2025 .</li></ul><h4>Cash Flows</h4><ul><li>Net Cash Used in Operating Activities: -$2,087,334 for the three months ended December 31, 2025, compared to -$1,517,203 for the three months ended December 31, 2024 .</li><li>Net Cash Provided by Financing Activities: $3,355,419 for the three months ended December 31, 2025, compared to $2,071,545 for the three months ended December 31, 2024 .</li><li>Cash and Cash Equivalents, End of Period: $12,051,748 for the three months ended December 31, 2025, compared to $1,563,502 for the three months ended December 31, 2024 .</li></ul><h4>Outlook</h4>Edesa Biotech, Inc. anticipates recruitment for its EB06 Phase 2 vitiligo study to commence midyear 2026, subject to regulatory approvals, with manufacturing plans reported to be on schedule . The company plans to present its Phase 3 respiratory and subgroup data at upcoming scientific and medical conferences and is exploring accelerated commercialization and broader strategic opportunities for paridiprubart . Management expects research expenditures to generally align with EB06 program activities and aims to achieve clinical objectives more efficiently by evaluating opportunities such as establishing investigational sites across multiple jurisdictions .

Edesa Biotech | 8-K: FY2026 Q1 Revenue: USD 0